Journal
NEUROLOGY
Volume 66, Issue 6, Pages 919-921Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000204294.28189.03
Keywords
-
Categories
Funding
- NCRR NIH HHS [M01 RR00044] Funding Source: Medline
- NIAID NIH HHS [U01 AI27658] Funding Source: Medline
- NIMH NIH HHS [P01 MH64570, R01 MH64409] Funding Source: Medline
Ask authors/readers for more resources
In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
